Press Releases :: Alzamend Neuro, Inc. (ALZN)

NASDAQ: ALZN

Mar 28, 2022 8:00am EDT

Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Dec 17, 2021 9:00am EST

Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Nov 30, 2021 8:30am EST

Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s

Sep 30, 2021 10:11am EDT

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease

Sep 13, 2021 6:30am EDT

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease

Aug 17, 2021 8:00am EDT

Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’s Disease in September 2021

Aug 04, 2021 6:30am EDT

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase Agreement with Digital Power Lending

Jul 30, 2021 6:30am EDT

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient’s Immunological System to Combat Alzheimer’s

Jul 28, 2021 3:07pm EDT

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Disease

Jul 23, 2021 6:30am EDT

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease

rss_feed News RSS

Subscribe to Our Newsletter

Making Alzheimer’s
Just a Memory^™

About

Investor Relations

Other